Global Clinical Trial Imaging Market - Segmented by Product and Service, Modality, End-User, and Geography - Growth, Trends, and Forecast (2022 - 2030)
The Global Clinical Trial Imaging Market is expected to register a CAGR of nearly 6.5% during 2018-2023 (the forecast period). Clinical Trial Imaging Market refers to solutions that support to various Pharmaceutical & Biotech companies and CRO’s, in trail designing and imaging services.
Growth In The Pharmaceutical And Biotechnology Companies
For most pharmaceutical and biotech companies clinical development and non-clinical services costs account for 85% of R&D budget which can be reduced by using CROs. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the total R&D expenditure for pharmaceutical was around Euro 35,000 million. The high expenditure on R&D is indicating the novel drug discoveries. The advancements in the science and technology are augmenting the growth of pharmaceutical companies across the globe. With the rise in the number of pharmaceuticals companies, the pharmaceutical industry is entering into the new era of advanced medical development.
The rise in the number of drug discoveries is augmenting the growth of clinical trials, the advancements in medical imaging technologies and rising adoption of the same across the globe is fuelling the demand for implementation of imaging technologies in clinical trials. The rise in the number of pharmaceutical and biotechnology companies is making it imperative for the manufacturers to deliver the best possible drug or medicine to the end user as competition is striking the companies. This factor is contributing to the rise of clinical trials as a large number of novel drug discoveries are being done by pharmaceutical and biotechnology companies. Digital Imaging and Communications in Medicine (DICOM) format and picture archiving and communication systems are needed in transmission of clinical imaging information in clinical trials
Other factors which are driving the Clinical Trial Imaging Market growth are rise in number of contract research organizations, and increase in research and development spending.
High Implementation Barriers and Costs of Imaging Systems
Clinical trials studies that has imaging-based primary endpoint, need an expertise individuals to read the images (e.g: left ventricular wall thickness or mitral inflow patterns in cardiovascular studies). If the trial is multicenter study the company may choose either centralized image interpretation (eg: bone or arthritic diseases trials) process that greatly enhance the credibility of image assessments and consistency of image assessments or site-specific image interpretation. For a multi-centre trial with imaging endpoints there are costs involved in standardizing the overall processes for image acquisition, data analysis and radiological review. Sponsors now select specialized CROs that manage end to end imaging processes.
Responsibilities can include generating imaging guidance documents, managing quality assurance steps, setting up mechanisms to transfer scans to a central location, performing quality control on scans received and the organization of independent radiological review and/or image analysis. Functional imaging techniques (PET/CT, CT perfusion imaging, DCE-MRI ) are not readily translatable into the Phase III clinical setting because of cost of implementing functional imaging techniques across a large patient cohort and lack of evidence that the imaging end point is sufficiently predictive of outcome. All the above factors are responsible to hinder the growth of clinical trial imaging market.
US Lead the Market in North America Region
Clinical trial imaging has developed extensively and now has an important role in many therapeutic areas as an endpoint. The clinical trial with multiple endpoints has medical imaging end point. The image data requirements were jointly guided by center for biologics evaluation and research (CBER) and the center for drug evaluation and research (CDER)
The FDA provides reference imaging guidelines for oncology clinical trials for medical imaging and biological products. Imaging core labs (ICLs) have become integral in clinical trials as they standardize the image data. Clinical trial imaging has central role that has imaging as an endpoint. The guidance is provided by Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), focusing on the image data requirements for submissions of medical imaging (contrast) agents and biological products.
Imaging service companies are expanding their expertise to multiple therapeutic areas and disease conditions and for medical devices (Eg: Catheters, Stents). All the above factors may propel the market growth over the forecasted period.
Key Developments in the Clinical Trial Imaging Market
• Mar 2018: Intrinsic Imaging, LLC, has completed a very large 12,480 read pivotal oncology clinical trial
Major players: BIOCLINICA, INC., BIOMEDICAL SYSTEMS CORPORATION, BIOTELEMETRY, INC., CARDIOVASCULAR IMAGING TECHNOLOGIES, LLC, ICON PLC, INTRINSIC IMAGING LLC, IXICO PLC, PAREXEL INTERNATIONAL CORPORATION, RADIANT SAGE LLC, AND WORLDCARE CLINICAL, LLC, among others.
Reasons to Purchase the Report
• Current and future Global Clinical Trial Imaging Market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
Growth In The Pharmaceutical And Biotechnology Companies
For most pharmaceutical and biotech companies clinical development and non-clinical services costs account for 85% of R&D budget which can be reduced by using CROs. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the total R&D expenditure for pharmaceutical was around Euro 35,000 million. The high expenditure on R&D is indicating the novel drug discoveries. The advancements in the science and technology are augmenting the growth of pharmaceutical companies across the globe. With the rise in the number of pharmaceuticals companies, the pharmaceutical industry is entering into the new era of advanced medical development.
The rise in the number of drug discoveries is augmenting the growth of clinical trials, the advancements in medical imaging technologies and rising adoption of the same across the globe is fuelling the demand for implementation of imaging technologies in clinical trials. The rise in the number of pharmaceutical and biotechnology companies is making it imperative for the manufacturers to deliver the best possible drug or medicine to the end user as competition is striking the companies. This factor is contributing to the rise of clinical trials as a large number of novel drug discoveries are being done by pharmaceutical and biotechnology companies. Digital Imaging and Communications in Medicine (DICOM) format and picture archiving and communication systems are needed in transmission of clinical imaging information in clinical trials
Other factors which are driving the Clinical Trial Imaging Market growth are rise in number of contract research organizations, and increase in research and development spending.
High Implementation Barriers and Costs of Imaging Systems
Clinical trials studies that has imaging-based primary endpoint, need an expertise individuals to read the images (e.g: left ventricular wall thickness or mitral inflow patterns in cardiovascular studies). If the trial is multicenter study the company may choose either centralized image interpretation (eg: bone or arthritic diseases trials) process that greatly enhance the credibility of image assessments and consistency of image assessments or site-specific image interpretation. For a multi-centre trial with imaging endpoints there are costs involved in standardizing the overall processes for image acquisition, data analysis and radiological review. Sponsors now select specialized CROs that manage end to end imaging processes.
Responsibilities can include generating imaging guidance documents, managing quality assurance steps, setting up mechanisms to transfer scans to a central location, performing quality control on scans received and the organization of independent radiological review and/or image analysis. Functional imaging techniques (PET/CT, CT perfusion imaging, DCE-MRI ) are not readily translatable into the Phase III clinical setting because of cost of implementing functional imaging techniques across a large patient cohort and lack of evidence that the imaging end point is sufficiently predictive of outcome. All the above factors are responsible to hinder the growth of clinical trial imaging market.
US Lead the Market in North America Region
Clinical trial imaging has developed extensively and now has an important role in many therapeutic areas as an endpoint. The clinical trial with multiple endpoints has medical imaging end point. The image data requirements were jointly guided by center for biologics evaluation and research (CBER) and the center for drug evaluation and research (CDER)
The FDA provides reference imaging guidelines for oncology clinical trials for medical imaging and biological products. Imaging core labs (ICLs) have become integral in clinical trials as they standardize the image data. Clinical trial imaging has central role that has imaging as an endpoint. The guidance is provided by Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), focusing on the image data requirements for submissions of medical imaging (contrast) agents and biological products.
Imaging service companies are expanding their expertise to multiple therapeutic areas and disease conditions and for medical devices (Eg: Catheters, Stents). All the above factors may propel the market growth over the forecasted period.
Key Developments in the Clinical Trial Imaging Market
• Mar 2018: Intrinsic Imaging, LLC, has completed a very large 12,480 read pivotal oncology clinical trial
Major players: BIOCLINICA, INC., BIOMEDICAL SYSTEMS CORPORATION, BIOTELEMETRY, INC., CARDIOVASCULAR IMAGING TECHNOLOGIES, LLC, ICON PLC, INTRINSIC IMAGING LLC, IXICO PLC, PAREXEL INTERNATIONAL CORPORATION, RADIANT SAGE LLC, AND WORLDCARE CLINICAL, LLC, among others.
Reasons to Purchase the Report
• Current and future Global Clinical Trial Imaging Market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
